Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185520 · ClinicalTrials.gov registry record
Young ESUS Patient Registry
A clinical trial, sponsored by Population Health Research Institute.
- Completed
- Registry status
- 535
- Enrollment target
NCT03185520: Completed study, sponsored by Population Health Research Institute.
NCT03185520 is a clinical trial that has completed, run by Population Health Research Institute. The registered enrollment target is 535 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185520 has completed, sponsored by Population Health Research Institute.
- COMPLETED
- Registry status
- 535 participants
- Enrollment target
Study Summary
This study seeks to determine the clinical characteristics of young ESUS patients using diagnostic criteria of the Cryptogenic Stroke / ESUS International Working Group, and to determine the rates of stroke recurrence, death, and hospital readmission in a contemporary cohort of young ESUS patients during follow-up of up to 18 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2020-12-17 |
What the finished NCT03185520 record still lists
NCT03185520 is an observational study that tracks outcomes without assigning an intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03185520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03185520 about?
NCT03185520 is a clinical study titled "Young ESUS Patient Registry". This study seeks to determine the clinical characteristics of young ESUS patients using diagnostic criteria of the Cryptogenic Stroke / ESUS International Working Group, and to determine the rates of stroke recurrence, death, and hospital readmission in a contemporary cohort of young ESUS patients d...
What is the current status of trial NCT03185520?
This trial is currently completed. The enrollment target is 535 participants. The study started on 2017-02-15. Estimated completion is 2020-12-17.
Who is sponsoring clinical trial NCT03185520?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI